More tools:Markets·Screener·Research·Chat

Veracyte, Inc. (VCYT) Financial Statements

Veracyte, Inc.
SIC 8071 · SERVICES-MEDICAL LABORATORIES
FIGI BBG001TSQWW0
XNAS · usd
42.45▼ 0.08 (-0.19%)
As of 2026-09-08
Valuation
Market Cap
Enterprise Value—
Trailing P/E
Price / Sales
EV / Revenue—
EV / EBITDA—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt—
Trading Information
Previous Close42.53
Day's Range41.57 – 43.28
52-Week Range29.45 – 60.91
Volume944.2K
Avg Volume1.4M
Share Statistics
Shares Outstanding
Employees755
ExchangeXNAS
Listed2013-10-30
Share count as of July 27, 2026
Loading Income Statement…
Key questions about Veracyte, Inc. (VCYT)
What is Veracyte, Inc.'s Market Cap?
Veracyte, Inc.'s Market Cap is $3.4B, based on as-reported figures from SEC (XBRL) filings.
What is Veracyte, Inc.'s Trailing P/E?
Veracyte, Inc.'s Trailing P/E is 29.8×, based on as-reported figures from SEC (XBRL) filings.
What is Veracyte, Inc.'s Price / Sales?
Veracyte, Inc.'s Price / Sales is 6.1×, based on as-reported figures from SEC (XBRL) filings.
What is Veracyte, Inc.'s Revenue (TTM)?
Veracyte, Inc.'s Revenue (TTM) is $561.9M, based on as-reported figures from SEC (XBRL) filings.
What is Veracyte, Inc.'s Net Income (TTM)?
Veracyte, Inc.'s Net Income (TTM) is $114.5M, based on as-reported figures from SEC (XBRL) filings.
What is Veracyte, Inc.'s EBITDA?
Veracyte, Inc.'s EBITDA is $126.6M, based on as-reported figures from SEC (XBRL) filings.
What is Veracyte, Inc.'s Diluted EPS (TTM)?
Veracyte, Inc.'s Diluted EPS (TTM) is 1.42, based on as-reported figures from SEC (XBRL) filings.
What is Veracyte, Inc.'s EBITDA Margin?
Veracyte, Inc.'s EBITDA Margin is 22.5%, based on as-reported figures from SEC (XBRL) filings.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Total revenue
YoY growth+15.5%+21.5%+18.5%+13.8%
Cost of revenue:
Cost of revenue————
Intangible asset amortization - cost of revenue
Total cost of revenue
Gross profit
% of revenue72.2%72.7%72.5%69.2%
Operating expenses:
Research and development
Selling and marketing
General and administrative
Impairment loss—
Intangible asset amortization - operating expenses
Total operating expenses
% of revenue56.9%56.5%46.1%51.8%
Income (loss) from operations
% of revenue15.3%16.3%26.4%17.4%
Other income, net
Income before income taxes
Income tax provision
Net income (loss)
% of revenue17.0%20.6%29.3%14.5%
Basic (in USD per share)
Diluted (in USD per share)